Alligator Bioscience Logo

Alligator Bioscience

Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.

ATORX | ST

Overview

Corporate Details

ISIN(s):
SE0000767188 (+8 more)
LEI:
549300E15VI0MB7LXV19
Country:
Sweden
Address:
C/O Medicon Village, 223 81 Lund

Description

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 10:46 Swedish 14.2 KB
2025-12-03 18:00
Alligator offentliggör tilläggsprospekt
Swedish 72.5 KB
2025-12-03 18:00
Alligator publishes supplement prospectus
English 75.9 KB
2025-12-03 08:45
Alligator Bioscience publishes financial calendar for 2026
English 66.6 KB
2025-12-03 08:45
Alligator Bioscience publicerar finansiell kalender för 2026
Swedish 67.1 KB
2025-12-02 10:49 Swedish 10.7 KB
2025-12-01 18:30
Alligator Bioscience enters into additional subscription undertakings and top g…
English 88.2 KB
2025-12-01 18:30
Alligator Bioscience ingår ytterligare tecknings- och toppgarantiåtaganden för …
Swedish 87.7 KB
2025-11-28 11:45
Alligator Bioscience publishes prospectus in connection with rights issue
English 84.1 KB
2025-11-28 11:45
Alligator Bioscience offentliggör prospekt i samband med företrädesemission
Swedish 83.9 KB
2025-11-27 10:10 Swedish 10.7 KB
2025-11-25 11:45
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
English 66.1 KB
2025-11-25 11:45
Kommuniké från extra bolagsstämma i Alligator Bioscience AB
Swedish 65.9 KB
2025-11-24 21:00
Alligator Bioscience offentliggör slutliga villkor i företrädesemission
Swedish 95.2 KB
2025-11-24 21:00
Alligator Bioscience announces final terms of rights issue
English 95.6 KB

Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alligator Bioscience

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alligator Bioscience via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-28 Peter Ostler Other Sell 1,658,134 179,045.31 SEK
2024-04-11 Staffan Encrantz Other Sell 44,108,581 47,196,181.67 SEK
2022-10-27 Sören Bregenholt Frederiksen Other Buy 52,000 72,748.00 SEK
2022-10-25 Marie Svensson Other Buy 12,000 16,632.00 SEK
2022-08-19 Sören Bregenholt Frederiksen Other Buy 13,906 25,726.10 SEK
2022-08-18 Sören Bregenholt Frederiksen Other Buy 31,094 56,911.35 SEK
2022-05-31 Peter Ostler Other Buy 100,000 151,500.00 SEK
2022-05-04 Sören Bregenholt Frederiksen Other Buy 30,000 50,895.00 SEK
2022-05-02 Sören Bregenholt Frederiksen Other Buy 30,000 50,811.00 SEK
2022-04-30 Sören Bregenholt Frederiksen Other Buy 30,000 51,171.00 SEK

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.